| Abstrakt: |
ᅟ: Chronic hepatitis B (CHB) infection is one of the main causes of chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC) worldwide. Long-term treatment with the most potent nucleos(t)ide analogues (NUCs), i.e., entecavir (ETV), tenofovir disoproxil fumarate (TDF), and the recently approved tenofovir alafenamide (TAF) are able to achieve and maintain virological suppression, and therefore are the first-line recommended therapies for all CHB patients.Purpose of Review: To assess the long-term outcome in CHB patients treated with NUCs.Recent Findings: These NUCs are highly effective in suppressing viral replication, thus preventing decompensation and reducing the risk of HCC. The 8-year survival of NUCs-treated patients is excellent, similar to that of the general population.Summary: Long-term virological suppression with NUCs can significantly improve the long-term outcomes of CHB patients. [ABSTRACT FROM AUTHOR] |
Full text from SpringerLink